The Effect of Intravitreal Ozurdex on DME After Cataract Surgery
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of OZURDEX (dexamethasone
intravitreal implant) 0.7 mg administered immediately after phacoemulsification and
intraocular lens implantation in type 1 or 2 diabetic patients to prevent the occurrence of
post-surgical macular edema (ME).
Treatment group: 24 patients will receive an intravitreal injection of OZURDEX at the end of
cataract surgery Patients will be seen at 1 week pre-operatively (baseline visit), and on the
same day post-surgery (visit 1), at 1 week (visit 2), 1 month (visit 3) and 3 months (visit
4).
BCVA, IOP and SD-OCT will be performed at each visit.